Fetal exposure to isotretinoin in Saudi Arabia: a multicenter real-world data analysis from 2015 to 2020
Authors:
Open Access
- 1 January 2024
- journal article
- research article
- Published by SAGE Publications in Therapeutic Advances in Drug Safety
- Vol. 15
Abstract
Background: Despite its high efficacy in treating severe acne, isotretinoin is associated with serious side effects, including teratogenicity. However, the extent of isotretinoin exposure during pregnancy in Saudi Arabia remains unknown. Objectives: This study aims to quantify the extent of fetal exposure to isotretinoin in Saudi Arabia and to evaluate adherence to risk minimization measures approved by the Saudi Food and Drug Authority. Design: Retrospective cohort study. Methods: This multicenter retrospective study included a cohort of 6233 women of childbearing ages (WCBAs) who had received isotretinoin therapy between 2015 and 2020. Exposure to isotretinoin use was ascertained from patients’ electronic health records and was defined as any positive pregnancy test (urine or serum) or any diagnosis or procedure related to pregnancy occurring during the risk period. We defined the risk period starting from isotretinoin initiation until up to 30 days after the last prescription. We quantified the overall incidence proportion of fetal exposure to isotretinoin by dividing the number of pregnancy cases during the risk period by the total study sample of WCBAs. Results: The cohort predominantly included young females (20–29 years), with a mean age of 24 years. Only 5% of the WCBAs used contraceptives, and 10% have a record of pregnancy testing. During the risk period, 34 pregnancies were identified, yielding a cumulative pregnancy incidence of 5.6 per 1000 WCBAs. Pregnancy outcomes for exposed women were about 5% of births had defects, while abortions accounted for 14.3% of pregnancies. Conclusion: Our investigation shows an alarming incidence of fetal exposure to isotretinoin in Saudi Arabia, substantially surpassing global estimates. These results underscore a critical need for enhanced interventions and robust risk minimization strategies tailored to the distinct challenges faced by the Saudi Arabian population.Keywords
Funding Information
- Deanship of Scientific Research, King Saud University (RSPD2024R1028)
This publication has 18 references indexed in Scilit:
- Measuring contraceptive method mix, prevalence, and demand satisfied by age and marital status in 204 countries and territories, 1970–2019: a systematic analysis for the Global Burden of Disease Study 2019The Lancet, 2022
- Awareness of isotretinoin use and Saudi FDA pregnancy prevention program in Riyadh, Saudi Arabia: A cross-sectional study among female patientsSaudi Pharmaceutical Journal, 2021
- Real-World Fetal Exposure to Acne Treatments in the United States: A Retrospective Analysis from 2006 to 2015Drug Safety, 2021
- Sexual and reproductive health knowledge, perceptions and experiences of women in Saudi Arabia: a qualitative studyEthnicity & Health, 2021
- Compliance with Pregnancy Prevention Recommendations for Isotretinoin in Estonia in 2012–2016Drugs - Real World Outcomes, 2018
- Epidemiology of acne vulgaris in adolescent male students in Arar, Kingdom of Saudi ArabiaJournal of the Egyptian Public Health Association, 2016
- High-Dose Isotretinoin Treatment and the Rate of Retrial, Relapse, and Adverse Effects in Patients With Acne VulgarisJAMA Dermatology, 2013
- Acne awareness and perception among population in Jeddah, Saudi ArabiaJournal of the Saudi Society of Dermatology & Dermatologic Surgery, 2013
- The impact of the iPLEDGE program on isotretinoin fetal exposure in an integrated health care systemJournal of the American Academy of Dermatology, 2011
- Retinoic Acid EmbryopathyNew England Journal of Medicine, 1985